Published

Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology
Date: 1999-06-01
Source: PubMed
DOI: 10.1016/s0893-133x(98)00089-x
PubMed: 10327426

Authors

Gouzoulis-Mayfrank E Schreckenberger M Sabri O Arning C Thelen B Spitzer M Kovar KA Hermle L Büll U Sass H

Watch author

Derived topics and classifications

psilocybin Pharmacology Mechanism of Action Healthy Volunteers Drug Interactions Other

Citation graph

0 referenced DOIs found in stored source metadata. 6 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Sex-specific increased reactivity of the PVT and prolonged PVT→CeA circuit engagement following psilocin administration2026-04-10 Psilocybin in Neuropsychiatric Disorders: Seeking Valuable Evidence in History, Pure Science, Clinical Trials and Real-World Data (RWD)2026-03-26 Neurovascular and neuroimaging effects of the hallucinogenic serotonin receptor agonist psilocin in the rat brain2015-12-01 Fungal Hallucinogens Psilocin, Ibotenic Acid, and Muscimol2013-08-01 Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man2002-09-01 Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG.1999-06-01

Related papers

Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelicsFrontiers in Psychiatry · 2024-11-06 Characterization of Altered Waking States of Consciousness in Healthy HumansClinicalTrials.gov · 2021-04-29